Valuation : Precision BioSciences, Inc.

Market Cap 198M 171M 161M 146M 275M 18.91B 276M 1.92B 737M 9.62B 743M 727M 30.39B P/E 2026 *
-1.98x
P/E 2027 * -2.65x
Enterprise Value 198M 171M 161M 146M 275M 18.91B 276M 1.92B 737M 9.62B 743M 727M 30.39B EV / Sales 2026 *
14.7x
EV / Sales 2027 * 22.3x
Free-Float
91.89%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Precision BioSciences, Inc.

1 day-0.97%
1 week-4.02%
Current month-6.15%
1 month-4.53%
3 months+16.21%
6 months+41.70%
Current year+72.36%
1 week 7.04
Extreme 7.035
7.49
1 month 7.04
Extreme 7.035
9.34
Current year 3.53
Extreme 3.53
9.62
1 year 3.53
Extreme 3.53
9.62
3 years 3.53
Extreme 3.53
19.43
5 years 3.53
Extreme 3.53
404.66
10 years 3.53
Extreme 3.53
710.11
Manager TitleAgeSince
Chief Executive Officer 48 14/10/2021
Chief Tech/Sci/R&D Officer 53 25/01/2006
Director of Finance/CFO 45 31/07/2026
Director TitleAgeSince
Chairman 68 31/10/2020
Director/Board Member 65 09/03/2020
Director/Board Member 67 11/04/2021
Date Insider Type Main position Quantity % Market Cap. Importance
01/08/26 Other

Chief Financial Officer

251,581 1.0451%
01/08/26 Other

Controller/Auditor

48,872 0.2030%
01/08/26 Other

Chief Technology Officer

236,188 0.9812%
Change 5-day change 1-year change 3-year change Capi.($)
-0.97%-4.02%+43.40%-44.42% 198M
-0.71%-6.35%-4.87%+9.03% 45.48B
+0.21%-2.98%+340.68%+519.93% 43.69B
+1.74%-2.24%+37.28%+21.57% 43.09B
+1.38%-3.28%+3.23%+65.60% 39.4B
-1.44%-5.26%+8.78%+36.85% 31.91B
+0.87%-2.60% - - 17.31B
+0.75%-0.64%+18.07%+110.32% 16.4B
-0.31%-2.78%+10.47%+30.49% 14.24B
+1.93%-3.55%+74.20%+39.37% 13.28B
Average +0.35%-3.62%+59.03%+87.64% 26.5B
Weighted average by Cap. +0.41%-3.67%+73.14%+123.43%

Financials

2026 *2027 *
Net sales 13.48M 11.62M 11M 9.97M 18.71M 1.29B 18.8M 131M 50.24M 655M 50.64M 49.53M 2.07B 8.88M 7.65M 7.24M 6.56M 12.31M 848M 12.37M 85.99M 33.07M 431M 33.33M 32.6M 1.36B
Net income -94.18M -81.15M -76.83M -69.64M -131M -9B -131M -913M -351M -4.58B -354M -346M -14.46B -96.95M -83.53M -79.09M -71.69M -134M -9.26B -135M -939M -361M -4.71B -364M -356M -14.89B
Net Debt - -
Logo Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical-stage gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company’s pipeline is comprised of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform is used to develop in vivo gene editing therapies for gene edits, including gene insertion, elimination, and excision. The Company's in vivo gene editing pipeline programs include PBGENE-HBV, PBGENE-3243, PBGENE-DMD, PBGENE-LIVER, PBGENE-CNS, PBGENE-NVS and iECURE-OTC. PBGENE-HBV is its lead in vivo gene editing program designed to eliminate cccDNA, the key source of replicating hepatitis B virus (HBV) and inactivating integrated HBV DNA in hepatocytes. Its PBGENE-3243 program is a first of its kind potential treatment for m.3243 associated mitochondrial disease. The Company's iECURE-OTC program is developed in partnership with iECURE, Inc.
Employees
67
Date Price Change Volume
11/09/26 US$7.170 -0.97% 191,404
10/09/26 US$7.240 -0.14% 143,427
09/09/26 US$7.250 -2.03% 273,502
08/09/26 US$7.400 -0.94% 139,956
04/09/26 US$7.470 +1.36% 124,284
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
7.170USD
Average target price
29.40USD
Spread / Average Target
+310.04%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DTIL Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!